If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Multiple Sclerosis Medicine & Life Sciences
Mesenchymal Stromal Cells Medicine & Life Sciences
Relapsing-Remitting Multiple Sclerosis Medicine & Life Sciences
Decision Making Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neuromyelitis Optica Medicine & Life Sciences
Autoimmune Experimental Encephalomyelitis Medicine & Life Sciences
Pregnancy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2016 2019

CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS

Pardini, M., Gualco, L., Bommarito, G., Roccatagliata, L., Schiavi, S., Solaro, C., Mancardi, G., Uccelli, A., Capello, E. & Inglese, M., Jun 1 2019, In : Multiple Sclerosis and Related Disorders. 31, p. 93-96 4 p.

Research output: Contribution to journalArticle

Oligoclonal Bands
Multiple Sclerosis
Cerebrospinal Fluid
White Matter
Healthy Volunteers

Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ

Massimi, L., Bukreeva, I., Santamaria, G., Fratini, M., Corbelli, A., Brun, F., Fumagalli, S., Maugeri, L., Pacureanu, A., Cloetens, P., Pieroni, N., Fiordaliso, F., Forloni, G., Uccelli, A., Kerlero de Rosbo, N., Balducci, C. & Cedola, A., Jan 1 2019, In : NeuroImage. 184, p. 490-495 6 p.

Research output: Contribution to journalArticle

Alzheimer Disease
Neurodegenerative Diseases

Fulminant Hepatitis Associated with Echovirus 25 during Treatment with Ocrelizumab for Multiple Sclerosis

Nicolini, L. A., Canepa, P., Caligiuri, P., Mikulska, M., Novi, G., Viscoli, C. & Uccelli, A., Jan 1 2019, In : JAMA Neurology.

Research output: Contribution to journalLetter

Mesenchymal Stromal Cells
Secretory Leukocyte Peptidase Inhibitor
Multiple Sclerosis

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): A randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Uccelli, A., Laroni, A., Brundin, L., Clanet, M., Fernandez, O., Nabavi, S. M., Muraro, P. A., Oliveri, R. S., Radue, E. W., Sellner, J., Soelberg Sorensen, P., Sormani, M. P., Wuerfel, J. T., Battaglia, M. A., Freedman, M. S., Bonetti, B., Rush, C., Herrera, C., Ramo Tello, C., Miller, D. & 23 othersSzwajcer, D., Strunk, D., Wall, D., Aguera-Morales, E., Rohde, E., Dazzi, F., Comi, G., Martino, G., Izquierdo Ayuso, G., Rabinovitch, H., MacLean, H., Marriott, J., Racosta, J., Arab, L., Gimona, M., Introna, M., Blinkenberg, M., Aghdami, N., Ali, R., Vosoughi, R., Nicholas, R., Marrie, R. A. & Karimi, S., May 9 2019, In : Trials. 20, 1, 263.

Research output: Contribution to journalArticle

Open Access
Phase II Clinical Trials
Clinical Trials, Phase I
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Multiple Sclerosis